Kornimate/medical-research-clean huggingface dataset:
microbes and respiratory illnesses

Conditions: Virus; Asthma

Summary: this study is called the microbes and respiratory illnesses (mari) study. children growing up on farms are exposed to many types of microbes that could be beneficial. it is thought that increased exposure to certain types of microbes early in life helps to develop a healthy immune system and reduce the risk for severe common cold illnesses, breathing problems, and allergies.

respiratory viruses, most notably rhinoviruses (rv), commonly infect school-age children during the month of september and are a well-known exposure for asthma exacerbations. allergic sensitization is a risk factor for increased viral respiratory illness burden and wheezing. nasal airway epithelial cell (naec) responses to viral exposure show distinct transcriptional programs that differ in individuals with allergies or asthma. there is a growing body of evidence strongly suggesting nasal airway microbial communities enriched in several commensal bacteria are associated with protection from symptomatic rv infections. metagenomic sequencing from previously collected nasal samples obtained at age 2 years showed distinct microbial communities and function in the traditional agrarian (ta) community cohort compared to farm and non-farm children. how the early life nasal microbial community can impact risk for viral respiratory infection symptoms and naec biology remains an important and unresolved question. to address this important question, this proposal includes an observational study to identify patterns of nasal airway gene expression among three cohorts of school-age children that markedly differ in their susceptibility to respiratory illnesses and wheezing: children from ta/amish communities, suburban children without asthma, and suburban children with asthma.

Eligibility criteria:
inclusion criteria: 1. participant and/or parent guardian must be able to understand and provide informed consent 2. children ages 4-12 years of age 3. cohort 1: family is self-identified as traditional agrarian (ta) community member 4. cohort 2: madison-area children with parental report of doctor-diagnosed asthma 5. cohort 3: madison-area children with no history of asthma by parental report 6. cohort 4: madison-area children who have an active respiratory illness exclusion criteria: 1. inability or unwillingness of a participant to give written informed consent or comply with study protocol 2. chronic sinusitis (frequent sinus infections) 3. plans to move out of the area before completing the study 4. past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study 5. enrolled family member
erg/eog study in amd patients treated with ranibizumab

Conditions: Age-Related Macular Degeneration

Summary: this is an open-label study assessing electrophysiologic testing of the retina with electoretinogram (erg) /electrooculogram (eog) tests in patients with exudative age-related macular degeneration (amd). the standard fda-approved treatment for wet amd is ranibizumab (lucentis). this study focuses on the erg and eog tests to evaluate retinal responses to ranibizumab treatment in amd.


Eligibility criteria:
inclusion criteria: * ability to provide written informed consent and comply with study assessments for the full duration of the study * age \>55 years * patients to be included in the study must have amd with choroidal neovascularization * bcva between 20/20 - 20/400 * lesion size less than or equal to 12 mps disc areas exclusion criteria: * prior treatment with an anti-vegf agent within 6 months of enrollment in this study * pregnancy (positive pregnancy test) * premenopausal women not using adequate contraception. the following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an iud, or contraceptive hormone implant or patch * prior enrollment in the study * any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated * participation in another simultaneous medical investigation or trial * media insufficient to obtain a view * other causes of cnv not related to amd * active ocular or peri-ocular infection * ocular surgery within 1 month prior to the study
study of mk-0663/etoricoxib in postorthopedic knee replacement surgery pain (mk-0663-098)

Conditions: Pain, Postoperative

Summary: the purpose of this study was to evaluate the efficacy and safety of etoricoxib compared to placebo and ibuprofen in the treatment of postoperative pain associated with unilateral total knee replacement surgery. the hypotheses for this study were that the average pain intensity difference (at rest) in participants treated with etoricoxib (120 mg, 90 mg) is superior to placebo, the average total daily dose of morphine in participants treated with etoricoxib (120 mg, 90 mg) is less than in participants treated with placebo, and that etoricoxib (120 mg, 90 mg) will be generally safe and well tolerated by participants treated for pain following total knee replacement orthopedic surgery.


Eligibility criteria:
inclusion criteria: - is in generally good health and is scheduled to have a total knee replacement exclusion criteria: * is allergic, intolerant to, or has a history of a significant clinical or laboratory adverse experience associated with etoricoxib or other cyclooxygenase-2 (cox-2) inhibitors/non-steroidal anti-inflammatory drugs (nsaids), ibuprofen, morphine, or oxycodone, or has hypersensitivity to aspirin, or other nsaids * has uncontrolled hypertension * is currently a user of any illicit drugs, or has a history of drug or alcohol abuse within the past 5 years
fuchs' torsional phaco study

Conditions: Fuchs' Endothelial Dystrophy; Phacoemulsification

Summary: the primary objective is to compare the effect of torsional phacoemulsification and longitudinal phacoemulsification on central and peripheral corneal thickness/volume after cataract surgery in patients with fuchs' endothelial dystrophy.

fuchs' endothelial dystrophy is a progressive, bilateral disease of the corneal endothelium, which eventually leads to corneal decompensation. in the early stage, some patients develop visually significant cataract. during cataract surgery ultrasound (us) power is used to emulsify the lens, which leads to endothelial cell loss and tissue damage. the reduction of us power has become the primary surgical goal in cataract surgery, which is especially important in patients with fuchs' endothelial dystrophy to limit endothelial cell loss. in 2006, alcon surgical introduced a torsional mode in its phacoemulsification system (infiniti vision system). it includes a handpiece that produces rotary oscillations of the phacoemulsification tip and is suggested to reduce the amount of us power required to remove the cataractous nucleus, because it does not produce repulsion and breaks up the cataract by shearing and not by the conventional jackhammer effect. this reduction in us power, could lead to less endothelial cell damage than the conventional (longitudinal) mode, which is reported recently for patients with hard cataract. it is important to investigate patients with fuchs' endothelial dystrophy, because patients with a compromised endothelial cell layer will benefit the most from less endothelial cell damage. consequently, this lower level of endothelial damage may postpone the date of keratoplasty.

Eligibility criteria:
inclusion criteria: * patients diagnosed with fuchs' endothelial dystrophy (all stages) and planning to undergo cataract surgery due to visually significant cataract * patients should be 40 years of age or older exclusion criteria: * patients with fuchs' dystrophy with a history of previous corneal or intraocular surgery * patients with a planned combined surgical procedure * patients who have other vision-affecting disorders than fuchs' endothelial dystrophy
a multicenter and real-world analysis of rc48-adc in patients with her2-positive or her2-low expressing, locally advanced or metastatic breast cancer

Conditions: Breast Cancer

Summary: evaluate the efficacy and safety of disitamb vedotin in patients with her2-positive or her2-low expressing, locally advanced or metastatic breast cancer

the main goal of this clinical trial is to examinie the utilization of rc48 in different her2 statuses, elucidating its clinical outcomes and safety, and investigating the factors that influence its clinical efficacy. the primary endpoint was the objective response rate (orr) assessed by the primary researcher. secondary endpoints included progression-free survival (pfs), overall survival (os), disease control rate (dcr), time to progression, and safety.

Eligibility criteria:
inclusion criteria: 1. histopathologically or imaging-confirmedlocally advanced or metastatic breast cancer ; 2. her2-positive or low status; 3. the function of major organswas normal, no treatmentcontraindications , andthe estimated survival time was more than 2 months; 4. at least one extracranialmeasurable lesion or osteolytic or mixed bone metastases inaccordance with the response evaluation criteria in solid tumors v. 1.1 (recist 1.1); 5. the clinical data were complete and traceable. exclusion criteria: 1. age \<18 ye ars old; 2. other concurrent cancers; 3. patients who rece ived rc48 as a neoadjuvant or adjuvant regimen； 4. incomplete medical data.

Keywords: her2-positive her2-low adc rc48
study comparing versajet with conventional surgical procedures in the removal of unhealthy tissue from lower limb ulcers

Conditions: Diabetic Foot; Varicose Ulcer; Pressure Ulcer

Summary: the purpose of this study is to compare the versajet™ device with conventional surgical procedures (performed with a scalpel) in the debridement (removal of unhealthy tissue) of lower limb ulcers. it is hypothesised that the time taken to debride lower limb ulcers will be quicker with the versajet™ device than with conventional surgical procedures.

this is prospective, comparative clinical evaluation to investigate whether there is a reduction in the skin-to-skin time of the first surgical debridement with versajet™, compared to conventional debridement techniques. skin-to-skin time is defined as the time of incision to the end time of debridement (wound ready for dressing application). conventional debridement is defined as scalpel plus pulse lavage. the purpose of this comparison is to demonstrate the resource savings which versajet™ may provide in terms of operating room (or) and personnel time, in addition to the potential to reduce the procedure, and possibly anaesthetic, time for the patient. it is envisaged that this information, combined with the costs associated with the procedure, will also provide valuable economic data to help justify the use of versajet™ from a financial perspective and support the future commercial success of the device.

Eligibility criteria:
inclusion criteria: * patients who are at least 18 years of age. * males and females (provided they are not pregnant or, if of reproductive age, are using contraception). * patients with a venous stasis, diabetic foot or decubitus reference ulcer located between the tibia and foot. * patients undergoing surgical debridement of their reference ulcer in the operating room (or). * patients undergoing their first surgical debridement of the reference ulcer. * patients suitable for debridement of their reference ulcer with both versajet™ and conventional debridement techniques. * patients who are able to understand the evaluation and are willing and able to provide written consent to participate in the evaluation. exclusion criteria: * patients with clinical signs of infection in the reference ulcer (e.g. purulence and / or odour). * patients with haemophilia * patients who have been treated with topical steroids, systemic immunosuppressants (including corticosteroids), anticoagulants or cytotoxic chemotherapy in the last 30 days, or who are anticipated to require such medications during the course of the study. * patients known to have acquired immunodeficiency syndrome (aids) or known to be infected with human immunodeficiency virus (hiv). * patients who suffer from acute or chronic bacterial, viral or fungal skin diseases that would interfere with wound healing. * patients with a known history of poor compliance with medical treatment. * patients who have participated in this evaluation previously or are currently participating in another clinical study.

Keywords: debridement hydrosurgery versajet leg ulcer
multicenter cohort study of invasive fungal filamentous fungal infections in liver transplant patients

Conditions: Fungal Infection

Summary: invasive filamentous fungal infections (aspergillosis, scedosporiosis, mucormycosis, fusarium wilt) are frequent and serious in immunocompromised individuals and especially in organ transplant patients. there is little recent data in liver transplantation, especially on the incidence and risk factors of fungal infections


Eligibility criteria:
inclusion criteria * age: from birth * subject with a liver transplant in one of the centers participating in the study * invasive fungal infection with filamentous fungus between 2007-2021 * proven or probable infection with filamentous fungi according to eortc/msgerc criteria: * invasive aspergillosis * mucormycosis * fusariosis * scedosporiosis * other infection with filamentous fungus * subject or legal representative for minors, who has not expressed, after information, his opposition to the reuse of his data for scientific research purposes. exclusion criteria * subject or (legal representative for minors) who has expressed his opposition to participating in the study * subject not with a liver transplant * subject under guardianship, curatorship or legal protection

Keywords: fungal infection immunodeficiency fungal filamentous liver transplant organ transplant
integrative medicine impact on frontline covid-19 personnel wellbeing

Conditions: Wellbeing of Healthcare Providersin Frontline COVID-19 Departments

Summary: treating covid-19 hospitalized patients incurred heavy burden of physical and emotional stress. the present study is taking place at carmel medical center in collaboration with the integrative oncology and the internal medicine teams with aim to improve the wellbeing of healthcare providers working in frontline covid-19 departments. in this prospective preference study, healthcare providers (hcps) working inside covid-19 departments are referred to integrative oncology-trained practitioners for assessment of their two leading concerns followed by 30-minute individually tailored treatment. the study assess, based on the measure yourself concerns and wellbeing (mycaw) questionnaire, the impact of personalized integrative oncology modalities on the physical and emotional concerns as well as heart rate variability of participating hcps in covid-19 departments.

background: treating covid-19 hospitalized patients incurred heavy burden of physical and emotional stress. the present study is taking place at carmel medical center in collaboration with the integrative oncology and the internal medicine teams with aim to improve the wellbeing of healthcare providers working in frontline covid-19 departments. purpose: to explore the impact of personalized integrative oncology modalities on the physical and emotional concerns as well as physiological parameters (e.g., heart rate variability, hrv) of healthcare practitioners (hcps) in covid-19 department. methods: in this prospective preference study, hcps working inside covid-19 departments are referred to integrative oncology-trained practitioners for assessment of their two leading concerns followed by 30-minute individually tailored treatment, scheduled during the working shift and performed adjacent to the covid department. integrative treatment include one or more of the following modalities: acupuncture, manual (e.g., acupressure, anthroposophic medicine, reflexology), movement (qigong, feldenkrais and paula methods), and mind-body therapies. the measure yourself concerns and wellbeing (mycaw) questionnaire is used for pre- and post-treatment quantitative and qualitative assessment. hcp's narratives analysis is purposed to identify concerns and impact of the integrative treatment program. hrv is assessed during the integrative treatment. three minutes intervals at start and after 20 minutes are used for pre- and post-treatment assessment. the primary outcome is rmssd (root square of successive differences) indicating parasympathetic activity. secondary outcomes are further parameters from the time domain analysis (sdnn, pnn50) and frequency domain analysis (lf/hf ratio).

Eligibility criteria:
inclusion criteria: \* healthcare providers and personnel working in frontline covid-19 hospital departments. exclusion criteria: \* personnel not consenting to participate

Keywords: integrative medicine resilience covid-19 quality of life
cell block immunohistochemistry in effusion cytology

Conditions: Effusion Pleural; Ascites; Pericardial Effusion

Summary: cytology is usually the first step in investigating serous effusions, to either detect or exclude an underlying malignancy. this study will try to answer the need for improved diagnostic yield of cytologic examination by cell block technique and immunohistochemical testing of three markers which are ezh2, claudin-4 and moc-31.

this is a prospective study that will be conducted at the pathology lab of assiut university hospital. the study will include effusion specimens (pleural, peritoneal \& pericardial) and the aspirated fluid will be examined for physical characters e.g. color and appearance. the sample will be divided into 2 equal parts: one for conventional smear preparation, and the other for cell block. a minimum of 2 thin smears will be prepared and stained with papanicolou stain. cell block sections of 4-6 μ thickness will be prepared and stained with the hematoxylin and eosin stain (h\&e). for immunohistochemistry, cell blocks will be used. expression of claudin 4, ezh2, and moc-31 will be evaluated in benign and malignant cells by using immunoperoxidase technique.

Eligibility criteria:
inclusion criteria: * all cases with serous effusion of unknown aetiology including ascites, pleural or pericardial effusions. exclusion criteria: * no exclusion criteria from the histopathologist perspective, i.e. all cases that undergone diagnostic aspiration are eligible for the study.

Keywords: immunohistochemistry cytology moc 31 monoclonal antibody, human
effects of parathyroid hormone in men with osteoporosis

Conditions: Osteoporosis

Summary: alendronate is a drug that blocks or reduces bone loss, while parathyroid hormone (pth) stimulates the formation of new bone. the purpose of this study is to compare the bone-building effects of pth alone, alendronate alone, and both pth and alendronate in men with osteoporosis over a two-and-a-half year period.

osteoporosis causes bones to weaken and break more easily. alendronate is used to treat or prevent osteoporosis. pth is a protein hormone that increases the calcium and phosphorus release from bone, leading to formation of new bone. this study will examine the changes in bone density measured at multiple places in the skeleton and changes in chemicals in the body that indicate bone breakdown and bone formation. the study will indicate whether some breakdown of bone is required for pth to have an overall bone-building effect in men. participants will be randomly assigned to receive pth alone by daily injection under the skin, alendronate alone taken by mouth, or both pth and alendronate. the study will last 2.5 years. all participants will receive some form of treatment for osteoporosis. blood, urine, and bone density tests will be performed at 6-month intervals. during the first 6 months, participants will come in for additional study visits. participants who complete the initial 2.5 years of their assigned treatment will be eligible for a 12 month extension to monitor bone density and bone turnover after pth is stopped. participants who were receiving alendronate will continue taking alendronate. the goal of this extension is to determine what happens to bone density and turnover after pth is stopped and whether alendronate is needed to prevent loss of pth-induced bone gain. participants who complete the 12 month extension while on their assigned treatment will be eligible for a second 12 month extension in which all participants receive pth therapy. participants who have been receiving alendronate continue taking alendronate. the goal of the second extension is to determine if responsiveness to pth is enhanced by a 12 month suspension of pth treatment.

Eligibility criteria:
inclusion criteria: * bone density of the spine or femoral neck two standard deviations below the mean of young adult men * normal renal and liver function tests, normal serum testosterone level, normal vitamin d and pth levels exclusion criteria: * significant cardiac, renal, hepatic, or malignant disease. * disorders (e.g., paget's disease, hyperthyroidism, hyperparathyroidism) or drugs (e.g., steroids, anticonvulsants, lithium, bisphosphonates, calcitonin, fluoride) known to affect bone metabolism * active peptic ulcer disease or severe reflux

Keywords: parathyroid hormone (pth) alendronate bone metabolism bone mineral density (bmd) bone loss postmenopausal osteoporosis osteoporosis in men
the effect of guided imagery on activity-specific balance confidence, pain, and psychological well-being

Conditions: Guided Imagery

Summary: the aim of this clinical trial is to evaluate the effect of guided imagery on activity-specific balance confidence, pain, and psychological well-being in elderly orthopedic patients. in the study, guided imagery will be applied by the researchers and will be applied over 2 days for a total of 3 repetitions. the study will be conducted in the postoperative period of the patients.


Eligibility criteria:
inclusion criteria: * patients who are open to communication and collaboration, * those who are over 65 years old, * those who have a mini-mental test score of 24 and above, * those who have the same type of analgesic protocol, * those who have a numerical pain score of at least 4 will be included. exclusion criteria: * patients who have developed any complications, * patients who have hearing, vision and perception problems, * patients who have been diagnosed with any psychiatric disease, * patients who have developed any complications after surgery will be excluded.

Keywords: orthopedics guided imagery pain psychological well-being